Revenue - (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Schedule of revenue by product and customer

The following table and description below reflect the products from which the Company generated its revenue:

	Three Months Ended September 30,				Nine Months Ended September 30,
Net revenue by product (in thousands)	2019		2018		2019		2018
MACI implants and kits
Implants based on contracted rates sold to or through a specialty pharmacy (a)	$	11,779	$	11,102	$	34,555	$	26,257
Implants subject to third-party reimbursement sold through a specialty pharmacy (b)	4,030		1,612		10,584		5,468
Implants sold direct based on contracted rates (c)	3,039		2,632		9,715		8,715
Implants sold direct subject to third-party reimbursement (d)	573		490		1,176		1,070
Biopsy kits - direct bill	533		488		1,632		1,392
Change in estimates related to prior periods	656		125		353		(273		)
Epicel
Direct bill (hospital)	9,889		6,035		20,445		16,893
Total revenue	$	30,499	$	22,484	$	78,460	$	59,522
(a) Represents implants sold through Orsini or AllCare in which such specialty pharmacy has entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contract. Also represents sales directly to DMS based on a contracted rate. Prior to June 15, 2018, the sales to Orsini represented here were based on a fixed transfer price under the distribution model.
(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.

Schedules of concentration of risk

The Company's total revenue and accounts receivable balances were comprised of the following concentrations from its largest customer of MACI and Epicel based on customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below and are as follows:

	Revenue Concentration								Accounts Receivable Concentration
	Three Months Ended September 30,				Nine Months Ended September 30,				September 30,		December 31,
	2019		2018		2019		2018		2019		2018
MACI	—	%	—	%	—	%	24	%	—	%	2	%
Epicel	10	%	5	%	9	%	9	%	6	%	4	%